<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> continues to intrigue investigators and clinicians alike as the new millennium begins </plain></SENT>
<SENT sid="1" pm="."><plain>A large number of publications in the past year have discussed issues of epidemiology, prevalence, detection, and treatment of <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> symptoms of <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo> were identified as a strong risk for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The relative frequency of short and long Barrett and cardia <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> in patients who undergo upper endoscopy have been better defined </plain></SENT>
<SENT sid="4" pm="."><plain>Biomarkers in patients with Barrett may eventually be helpful in identifying those at high risk for the development of <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>High-dose proton pump inhibition to the point of near elimination of esophageal acid exposure remains disappointing in its impact on the surface area of Barrett </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, the developments in endoscopic therapy for patients with <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> continue to be promising </plain></SENT>
</text></document>